0
Chest Infections |

Population-Based Risk of Mycobacterial Infections Associated With Anti-Tumor Necrosis Factor (anti-TNF) Therapy in Older Patients in Ontario, Canada

Sarah Brode, MD; Frances Jamieson, MD; Ryan Ng, BS; Michael Campitelli, MPH; Jeff Kwong, MD; J. Paterson, MS; Ping Li, BS; Alexandre Marchand-Austin, BS; Claire Bombardier, MD; Theodore Marras, MD
Author and Funding Information

Joint Division of Respirology, Department of Medicine, University Health Network and Mount Sinai Hospital, Toronto, ON, Canada


Chest. 2013;144(4_MeetingAbstracts):270A. doi:10.1378/chest.1704023
Text Size: A A A
Published online

Abstract

SESSION TITLE: TB

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Sunday, October 27, 2013 at 03:00 PM - 04:00 PM

PURPOSE: Anti-TNF therapy increases the risk of tuberculosis (TB), but whether it affects the risk of nontuberculous mycobacterial (NTM) disease is unclear.

METHODS: We conducted a cohort study, following all residents of Ontario, Canada aged >65 years from January 2001 to December 2010. We assessed the risk of TB and NTM disease associated with anti-TNF therapy in all subjects and amongst a subpopulation with rheumatoid arthritis (RA; defined using a validated algorithm based on hospital discharge abstracts and physician service claims). We obtained data on all cases of laboratory-confirmed mycobacterial infection from Public Health Ontario Laboratory.

RESULTS: In our study population, 3,481 patients had ever used anti-TNF agents and 2,666,961 had not. Among anti-TNF ever-users, 82% had RA. We observed TB case rates among anti-TNF ever-users and never-users of 31.7 (95%CI: 12.7-65.4) and 6.9 (95%CI: 6.5-7.3) per 100,000 person-years, respectively, for a rate ratio (RR; comparing anti-TNF ever-users to never-users) of 4.62 (95%CI: 2.20-9.71). In contrast, we observed NTM disease rates among anti-TNF ever-users and never-users of 81.8 (95%CI: 48.5-129.3) and 27.6 (95%CI: 26.8-28.4) per 100,000 person-years, respectively, for a RR of 2.96 (95%CI: 1.86-4.70). Among the RA subpopulation, we observed TB case rates among anti-TNF ever-users and never-users of 41.6 (95% CI: 16.7-85.7) and 10.2 (95%CI: 6.9-14.5) per 100,000 person-years, respectively, for a RR of 4.08 (95%CI: 1.80-9.27). Among the RA subpopulation, we observed NTM disease rates among anti-TNF ever-users and never-users of 89.4 (95%CI: 50.0-147.4) and 60.3 (95%CI: 51.9-69.7) per 100,000 person-years, respectively, for a RR of 1.48 (95%CI: 0.88-2.51).

CONCLUSIONS: In Ontario, NTM disease occurs more frequently than TB in anti-TNF users. Anti-TNF therapy is associated with an increased risk of mycobacterial infections, and the increased risk may be greater for TB than NTM disease. In RA patients, anti-TNF therapy increases the risk of TB, but not NTM disease.

CLINICAL IMPLICATIONS: Anti-TNF therapy is a risk factor for mycobacterial disease. RA patients are at elevated risk of NTM, but that risk is not substantially altered by anti-TNF therapy.

DISCLOSURE: The following authors have nothing to disclose: Sarah Brode, Frances Jamieson, Ryan Ng, Michael Campitelli, Jeff Kwong, J. Paterson, Ping Li, Alexandre Marchand-Austin, Claire Bombardier, Theodore Marras

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543